liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
Univ Minnesota, MN 55455 USA.
Univ Minnesota, MN 55455 USA.
Univ Minnesota, MN 55455 USA.
Univ Virginia, VA 22908 USA.
Vise andre og tillknytning
2019 (engelsk)Inngår i: International Journal of Molecular Sciences, ISSN 1422-0067, E-ISSN 1422-0067, Vol. 20, nr 1, artikkel-id 229Artikkel, forskningsoversikt (Fagfellevurdert) Published
Abstract [en]

Ovarian cancer is the leading cause of death from gynecologic malignancy in the Western world. This is due, in part, to the fact that despite standard treatment of surgery and platinum/paclitaxel most patients recur with ultimately chemoresistant disease. Ovarian cancer is a unique form of solid tumor that develops, metastasizes and recurs in the same space, the abdominal cavity, which becomes a unique microenvironment characterized by ascites, hypoxia and low glucose levels. It is under these conditions that cancer cells adapt and switch to mitochondrial respiration, which becomes crucial to their survival, and therefore an ideal metabolic target for chemoresistant ovarian cancer. Importantly, independent of microenvironmental factors, mitochondria spatial redistribution has been associated to both tumor metastasis and chemoresistance in ovarian cancer while specific sets of genetic mutations have been shown to cause aberrant dependence on mitochondrial pathways in the most aggressive ovarian cancer subtypes. In this review we summarize on targeting mitochondria for treatment of chemoresistant ovarian cancer and current state of understanding of the role of mitochondria respiration in ovarian cancer. We feel this is an important and timely topic given that ovarian cancer remains the deadliest of the gynecological diseases, and that the mitochondrial pathway has recently emerged as critical in sustaining solid tumor progression.

sted, utgiver, år, opplag, sider
MDPI , 2019. Vol. 20, nr 1, artikkel-id 229
Emneord [en]
ascites; OXPHOS; mitochondrial inhibitor; chemoresistant ovarian cancer; SWI; SNF complex
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-155620DOI: 10.3390/ijms20010229ISI: 000459747700229PubMedID: 30626133OAI: oai:DiVA.org:liu-155620DiVA, id: diva2:1297726
Merknad

Funding Agencies|Department of Defense Ovarian Cancer Research Program [OC160377]; Minnesota Ovarian Cancer Alliance; Randy Shaver Cancer Research Funds

Tilgjengelig fra: 2019-03-20 Laget: 2019-03-20 Sist oppdatert: 2019-08-29

Open Access i DiVA

fulltext(1438 kB)100 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1438 kBChecksum SHA-512
2c5a4309ea0f0afac25ded9350451d2a7ce7e16c4df036c2a8f3c89b30add21facb54afcbb1fc647d68bf07344f9caf6b0142fd9f149a1ac22e398f1069f9a9b
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Linder, Stig
Av organisasjonen
I samme tidsskrift
International Journal of Molecular Sciences

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 100 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 119 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf